Cowen Reiterates “Buy” Rating for Aptinyx (NASDAQ:APTX)
Cowen reissued their buy rating on shares of Aptinyx (NASDAQ:APTX) in a research note published on Monday, AnalystRatings.com reports.
Several other brokerages have also recently weighed in on APTX. Zacks Investment Research upgraded Aptinyx from a hold rating to a buy rating and set a $4.75 price objective for the company in a report on Wednesday, March 27th. BMO Capital Markets restated an outperform rating on shares of Aptinyx in a report on Friday, March 22nd. Finally, Cantor Fitzgerald decreased their price objective on Aptinyx from $18.00 to $12.00 and set an overweight rating for the company in a report on Friday, March 22nd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Aptinyx has a consensus rating of Buy and a consensus target price of $12.95.
Shares of NASDAQ APTX opened at $3.07 on Monday. The stock has a market capitalization of $105.05 million and a PE ratio of -1.16. Aptinyx has a fifty-two week low of $2.88 and a fifty-two week high of $32.25.
In other Aptinyx news, Director Henry O. Gosebruch purchased 100,000 shares of Aptinyx stock in a transaction that occurred on Wednesday, May 8th. The stock was acquired at an average price of $3.86 per share, for a total transaction of $386,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 8.47% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Great West Life Assurance Co. Can bought a new position in Aptinyx during the fourth quarter worth about $40,000. Gabelli Funds LLC bought a new position in Aptinyx during the first quarter worth about $44,000. Dimensional Fund Advisors LP bought a new position in Aptinyx during the first quarter worth about $57,000. Legal & General Group Plc bought a new position in Aptinyx during the third quarter worth about $58,000. Finally, Alambic Investment Management L.P. bought a new position in Aptinyx during the first quarter worth about $87,000. Institutional investors and hedge funds own 58.37% of the company’s stock.
Aptinyx Company Profile
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
See Also: Initial Public Offering (IPO)
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.